RARE — Ultragenyx Pharmaceutical Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1515673 ·
Last close
$15.48
Market Cap
$1.53B
52W High
$39.89
52W Low
$12.73
ADV30
6,073,485
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 214,000,000 | 180,000,000 | -75,000,000 | -92,000,000 | 1,264,000,000 | 125,000,000 | 1,548,000,000 |
| Mar 2026 | 136,000,000 | 106,000,000 | -169,000,000 | -185,000,000 | 1,296,000,000 | 175,000,000 | 1,525,000,000 |
| Dec 2025 | 207,279,000 | 177,934,000 | -113,283,000 | -128,556,000 | 1,532,000,000 | 421,000,000 | 1,605,000,000 |
| Sep 2025 | 159,933,000 | 131,942,000 | -170,890,000 | -180,413,000 | 1,190,445,000 | 202,510,000 | 1,174,286,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-485,000,000
Investing CF
$40,000,000
Financing CF
$477,806,000
CapEx
$-9,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.84
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,809,000,000
Inventory
$59,000,000
Receivables
$200,000,000
ST Investments
$167,000,000
EBIT TTM
$-505,609,000
Pretax Income TTM
$-582,226,000
Interest Exp TTM
$76,617,000
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$717,000,000
EBITDA
$-465,000,000
Free Cash Flow
$-221,787,008
Enterprise Value
$2,322,530,816
Total Cash
$292,000,000
Total Debt
$1,202,000,000
Shares Out
98,588,873
Trailing EPS
$-5.83
Book Value
$-2.96
ROE
—
ROA
-24.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 673,000,000 | -535,000,000 | -575,000,000 | 1,532,000,000 | 1,605,000,000 | -80,000,000 | -466,000,000 |
| Dec 2024 | 560,000,000 | -536,000,000 | -569,000,000 | 1,503,000,000 | 1,241,000,000 | 255,000,000 | -414,000,000 |
| Dec 2023 | 434,000,000 | -569,000,000 | -607,000,000 | 1,491,013,000 | 1,215,599,000 | 275,414,000 | -475,000,000 |
| Dec 2022 | 363,329,000 | -648,919,000 | -707,421,000 | 1,545,444,000 | 1,192,950,000 | 352,494,000 | -380,465,000 |
TTM Snapshot
Revenues TTM
$669,708,000
NetIncome TTM
$-608,920,000
OpCashFlow TTM
—
Assets (Latest)
$1,296,000,000
Forward EPS
$0.20
Max Pain — expiry 2026-10-16
max pain strike: $15.00 · spot: $15.48 · call oi: 25,015 · put oi: 14,194Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INVA | Innoviva, Inc. | $1.53B | $21.21 | — |
| SNDX | Syndax Pharmaceuticals Inc | $1.52B | $16.99 | — |
| KRSA | Korsana Biosciences, Inc. | $1.54B | $33.92 | — |
| KLRA | Kailera Therapeutics, Inc. | $1.51B | $11.61 | — |
| QURE | uniQure N.V. | $1.57B | $22.59 | — |
News headlines (Yahoo Finance, 1h cache)
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
2026-10-08 13:49 · Yahoo
Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?
2026-10-08 10:08 · Yahoo
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million
2026-10-07 16:00 · Yahoo
Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity
2026-10-07 15:51 · Yahoo
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
2026-10-07 12:30 · Yahoo
Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone?
2026-10-07 00:16 · Yahoo
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
2026-10-05 14:46 · Yahoo
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
2026-10-02 06:00 · Yahoo
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
2026-09-22 19:09 · Yahoo
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
2026-09-22 10:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.